Molecular pathogenesis of pancreatic ductal adenocarcinoma and clinical implications

被引:23
|
作者
Magee, CJ [1 ]
Greenhalf, W [1 ]
Howes, N [1 ]
Ghaneh, P [1 ]
Neoptolemos, JP [1 ]
机构
[1] Royal Liverpool Univ Hosp, Dept Surg, Liverpool L69 3GA, Merseyside, England
来源
SURGICAL ONCOLOGY-OXFORD | 2001年 / 10卷 / 1-2期
关键词
pancreatic cancer; hereditary pancreatitis; pathogenesis; screening; treatment;
D O I
10.1016/S0960-7404(01)00016-0
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Pancreatic ductal adenocarcinoma (PDAC) is a significant cause of cancer death worldwide. PDAC is also one of the best-studied cancers with regard to molecular pathogenesis. The chief risk factors associated with PDAC are smoking and pancreatitis, in addition genetic predisposition seems to play a major role. This genetic predisposition may in some cases be indirect, for example via the elevated risk of pancreatitis seen in patients with hereditary pancreatitis (HP). The elucidation of the molecular causes of PDAC has enabled the provision of secondary screening for PDAC in conditions such as HP. This review is concerned with the molecular pathogenesis of PDAC and the application of this basic scientific understanding into state-of-the-art clinical practice. (C) 2001 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:1 / 23
页数:23
相关论文
共 50 条
  • [41] Immunotherapy for pancreatic ductal adenocarcinoma: an overview of clinical trials
    Alessandro Paniccia
    Justin Merkow
    Barish H.Edil
    Yuwen Zhu
    Chinese Journal of Cancer Research, 2015, 27 (04) : 376 - 391
  • [42] Clinical study of genomic drivers in pancreatic ductal adenocarcinoma
    Michael T Barrett
    Ray Deiotte
    Elizabeth Lenkiewicz
    Smriti Malasi
    Tara Holley
    Lisa Evers
    Richard G Posner
    Timothy Jones
    Haiyong Han
    Mark Sausen
    Victor E Velculescu
    Jeffrey Drebin
    Peter O'Dwyer
    Gayle Jameson
    Ramesh K Ramanathan
    Daniel D Von Hoff
    British Journal of Cancer, 2017, 117 : 572 - 582
  • [43] The clinical relevance of the Hippo pathway in pancreatic ductal adenocarcinoma
    Richard Drexler
    Mirco Küchler
    Kim C. Wagner
    Tim Reese
    Bernd Feyerabend
    Moritz Kleine
    Karl J. Oldhafer
    Journal of Cancer Research and Clinical Oncology, 2021, 147 : 373 - 391
  • [44] Pancreatic ductal adenocarcinoma
    Gallmeier, E.
    Gress, T. M.
    INTERNIST, 2018, 59 (08): : 805 - 822
  • [45] Clinical study of genomic drivers in pancreatic ductal adenocarcinoma
    Barrett, Michael T.
    Deiotte, Ray
    Lenkiewicz, Elizabeth
    Malasi, Smriti
    Holley, Tara
    Evers, Lisa
    Posner, Richard G.
    Jones, Timothy
    Han, Haiyong
    Sausen, Mark
    Velculescu, Victor E.
    Drebin, Jeffrey
    O'Dwyer, Peter
    Jameson, Gayle
    Ramanathan, Ramesh K.
    Von Hoff, Daniel D.
    BRITISH JOURNAL OF CANCER, 2017, 117 (04) : 572 - 582
  • [46] Analysis of clinical significance of BRCAness in pancreatic ductal adenocarcinoma
    Tadehara, Masayoshi
    Kato, Takuya
    Adachi, Kai
    Sakurai, Yasutaka
    Ichinoe, Masaaki
    Murakumo, Yoshiki
    CANCER SCIENCE, 2021, 112 : 810 - 810
  • [47] Immunotherapy for pancreatic ductal adenocarcinoma: an overview of clinical trials
    Paniccia, Alessandro
    Merkow, Justin
    Edil, Barish H.
    Zhu, Yuwen
    CHINESE JOURNAL OF CANCER RESEARCH, 2015, 27 (04) : 376 - 391
  • [48] The clinical relevance of the Hippo pathway in pancreatic ductal adenocarcinoma
    Drexler, Richard
    Kuchler, Mirco
    Wagner, Kim C.
    Reese, Tim
    Feyerabend, Bernd
    Kleine, Moritz
    Oldhafer, Karl J.
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2021, 147 (02) : 373 - 391
  • [49] Pancreatic Ductal Adenocarcinoma
    Heinemann, V.
    Schmidberger, H.
    ONKOLOGE, 2019, 25 (08): : 642 - 644
  • [50] Pancreatic ductal adenocarcinoma
    Gallmeier, E.
    Gress, T. M.
    GASTROENTEROLOGE, 2019, 14 (02): : 131 - 148